Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?
Therapy for the inflammatory bowel diseases increasingly includes the use of immune-modifying and biologic therapies. Recently, in young patients with IBD, an association has been noted between the use of infliximab along with concomitant purine analogues and the development of hepatosplenic T-cell lymphoma (HSTCL)-a rare and all but incurable form of non-Hodgkin's lymphoma. This report briefly reviews the issue of lymphoma and IBD therapy. Additionally, a description of HSTCL and a summary of the known cases of this apparent therapeutic complication are presented. Clinical options in light of this new information are explored.
Rosh
Joel R
JR
Goryeb Children's Hospital/Atlantic Health, Morristown, New Jersey, USA. joel.rosh@atlantichealth.org
Gross
Thomas
T
Mamula
Petar
P
Griffiths
Anne
A
Hyams
Jeffrey
J
D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D002648:Child; D003424:Crohn Disease / Q000150:complications* / Q000188:drug therapy; D005260:Female; D006801:Humans; D000069285:Infliximab; D008113:Liver Neoplasms / Q000139:chemically induced / Q000209:etiology*; D016399:Lymphoma, T-Cell / Q000139:chemically induced / Q000209:etiology*; D008297:Male; D013160:Splenic Neoplasms / Q000139:chemically induced / Q000209:etiology*
D000911:Antibodies, Monoclonal; D000069285:Infliximab